The ratio between effector CD8+ cells and Treg in TME is found to positively correlate with prognosis in melanoma patients, which offered a basis for Treg depletion strategies to evolve as potential contributors to ICI therapy [62,86]. The gene discussed is CD8A; the disease is melanoma.